title: Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study.
abstract: OBJECTIVE
  To determine whether 3 months of topical latanoprost treatment caused proliferative or degenerative effects on the peripheral iris of patients with glaucoma.
  
  
  METHODS
  Seventeen patients requiring filtering surgery for primary open-angle glaucoma or pseudoexfoliation glaucoma were randomized to receive topical latanoprost for 3 months (n = 8) or alternative medication (n = 9) before surgery. A trabeculectomy and a peripheral iridectomy specimen was obtained from each patient during surgery. The tissue was subjected to histological and immunohistochemical evaluation using 2 cell cycle markers: proliferating cell nuclear antigen and nuclear-associated protein (Ki-67).
  
  
  RESULTS
  No degenerative or pathological changes were seen in the latanoprost-treated irides, including the one specimen in this series in which there was an eye color change. Proliferating cell nuclear antigen and nuclear-associated protein markers were negative for changes in all the test specimens.
  
  
  CONCLUSIONS
  Short-term treatment with latanoprost does not produce morphological changes or cellular proliferation changes in the iris.
authors.affiliation: Department of Ophthalmology, Mainz University, Langenbeckstrasse 1, 55131 Mainz, Germany. pfeiffer@augen.klinik.uni-mainz.de
authors.forename: N
authors.initials: N
authors.lastname: Pfeiffer
authors.forename: I
authors.initials: I
authors.lastname: Grierson
authors.forename: H
authors.initials: H
authors.lastname: Goldsmith
authors.forename: D
authors.initials: D
authors.lastname: Hochgesand
authors.forename: A
authors.initials: A
authors.lastname: Winkgen-Böhres
authors.forename: P
authors.initials: P
authors.lastname: Appleton
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D015415:Biomarkers; D017889:Exfoliation Syndrome / Q000150:complications; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D006801:Humans; D007124:Immunoenzyme Techniques; D007429:Intraocular Pressure / Q000187:drug effects*; D007498:Iris / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D019394:Ki-67 Antigen / Q000378:metabolism; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D016037:Single-Blind Method; D014130:Trabeculectomy
chemical_list: D000959:Antihypertensive Agents; D015415:Biomarkers; D019394:Ki-67 Antigen; D009883:Ophthalmic Solutions; D018809:Proliferating Cell Nuclear Antigen; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost